Katja Simon-Keller

Katja Simon-Keller

Auto-generated profile, based on publicly available information

Katja Simon-Keller

Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SRSarada Devi Ramachandran
Sarada Devi Ramachandran
KSKatharina Schirmer
Katharina Schirmer
BMBernhard Münst
Bernhard Münst
SHStefan Heinz
Stefan Heinz
SGShahrouz Ghafoory
Shahrouz Ghafoory
KBKatja Breitkopf-Heinlein
Katja Breitkopf-Heinlein
In this study we used differentiated adult human upcyte® cells for the in vitro generation of liver organoids. Upcyte® cells are genetically engineered cell strains derived from primary human cells by lenti-viral transduction of genes or gene combinations inducing transient proliferation capacity (upcyte® process). Proliferating upcyte® cells undergo a finite number of cell divisions, i.e., 20 to 40 population doublings, but upon withdrawal of proliferation stimulating factors, they regain most of the cell specific characteristics of primary cells. When a defined mixture of differentiated human upcyte® cells (hepatocytes, liver sinusoidal endothelial cells (LSECs) and mesenchymal stem cells (MSCs)) was cultured in vitro on a thick layer of Matrigel™, they self-organized to form liver organoid-like structures within 24 hours. When further cultured for 10 days in a bioreactor, these liver organoids show typical functional characteristics of liver parenchyma including activity of cytochromes P450, CYP3A4, CYP2B6 and CYP2C9 as well as mRNA expression of several marker genes and other enzymes. In summary, we hereby describe that 3D functional hepatic structures composed of primary human cell strains can be generated in vitro. They can be cultured for a prolonged period of time and are potentially useful ex vivo models to study liver functions.

20 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
VRVladimir Riabov
Vladimir Riabov
SYShuiping Yin
Shuiping Yin
BSBin Song
Bin Song
AAAida Avdic
Aida Avdic
KSKai Schledzewski
Kai Schledzewski
Julia KzhyshkowskaJulia Kzhyshkowska
Julia Kzhyshkowska
Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model

27 September 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ABAnja Becker
Anja Becker
AKAnna Klapczynski
Anna Klapczynski
NKNatalia Kuch
Natalia Kuch
FAFabiola Arpino
Fabiola Arpino
KSKatja Simon-Keller
Katja Simon-Keller
NGNorbert Gretz
Norbert Gretz
Photobiomodulation (PBM) with blue light induces a biphasic dose response curve in proliferation of immortalized human keratinocytes (HaCaT), with a maximum anti-proliferative effect reached with 30min (41.4 J/cm2). The aim of this study was to test the photobiomodulatory effect of 41.4 J/cm2 blue light irradiation on ROS production, apoptosis and gene expression at different time points after irradiation of HaCaT cells in vitro and assess its safety. ROS concentration was increased 30 min after irradiation. However, already 1 h after irradiation, cells were able to reduce ROS and balance the concentration to a normal level. The sudden increase in ROS did not damage the cells, which was demonstrated with FACS analysis where HaCaT cells did not show any sign of apoptosis after blue light irradiation. Furthermore, a time course could be seen in gene expression analysis after blue light, with an early response of stimulated genes already 1 h after blue light irradiation, leading to the discovery of the aryl hydrocarbon receptor as possible target for blue light irradiation.

25 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JKJakob Nikolas Kather
Jakob Nikolas Kather
CHChristian Hörner
Christian Hörner
CWCleo-Aron Weis
Cleo-Aron Weis
TAThiha Aung
Thiha Aung
CVChristian Vokuhl
Christian Vokuhl
KSKatja Simon-Keller
Katja Simon-Keller
Rhabdomyosarcomas (RMS) are rare and often lethal diseases. It is assumed that the tumor microenvironment (TME) of RMS exerts an immunosuppressive function, but there is currently no systematic analysis of the immune cells infiltrating sarcoma tissue. Focusing on two common types of RMS (alveolar [RMA] and embryonal [RME]), we performed a comprehensive immunohistochemical analysis of tumor-infiltrating immune cells in the TME. We performed a qualitative estimation of infiltrating immune cells in the tumor microenvironment by an experienced pathologist as well as a quantitative digital pathology analysis. We found that (1) manual and automatic quantification of tumor-infiltrating immune cells were consistent; (2) RME tumors showed a higher degree of immune cell infiltration than RMA tumors but (3) the number of tumor infiltrating lymphocytes was low compared to other solid tumor types; (4) microvascular density correlated with immune cell infiltration and (5) CD163 positive macrophages as well as CD54 positive microvessels were more often detected in RME than in RMA and correlated with patient overall and event free survival. Our systematic analysis provides a comprehensive view of the immune landscape of RMS which needs to be taken into account for developing immunotherapies for this rare type of cancer.

15 May 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
OCOrla T. Cox
Orla T. Cox
SEShelley J. Edmunds
Shelley J. Edmunds
KSKatja Simon-Keller
Katja Simon-Keller
BLBo Li
Bo Li
BMBruce Moran
Bruce Moran
Rosemary O’ConnorRosemary O’Connor
Rosemary O’Connor
The PDLIM2 protein regulates stability of transcription factors including NF-κB and STATs in epithelial and hemopoietic cells. PDLIM2 is strongly expressed in certain cancer cell lines that exhibit an epithelial-to-mesenchymal phenotype, and its suppression is sufficient to reverse this phenotype. PDLIM2 supports the epithelial polarity of nontransformed breast cells, suggesting distinct roles in tumor suppression and oncogenesis. To better understand its overall function, we investigated PDLIM2 expression and activity in breast cancer. PDLIM2 protein was present in 60% of tumors diagnosed as triple-negative breast cancer (TNBC), and only 20% of other breast cancer subtypes. High PDLIM2 expression in TNBC was positively correlated with adhesion signaling and β-catenin activity. Interestingly, PDLIM2 was restricted to the cytoplasm/membrane of TNBC cells and excluded from the nucleus. In breast cell lines, PDLIM2 retention in the cytoplasm was controlled by cell adhesion, and translocation to the nucleus was stimulated by insulin-like growth factor-1 or TGFβ. Cytoplasmic PDLIM2 was associated with active β-catenin and ectopic expression of PDLIM2 was sufficient to increase β-catenin levels and its transcriptional activity in reporter assays. Suppression of PDLIM2 inhibited tumor growth in vivo, whereas overexpression of PDLIM2 disrupted growth in 3D cultures. These results suggest that PDLIM2 may serve as a predictive biomarker for a large subset of TNBC whose phenotype depends on adhesion-regulated β-catenin activity and which may be amenable to therapies that target these pathways. Significance: This study shows that PDLIM2 expression defines a subset of triple-negative breast cancer that may benefit from targeting the β-catenin and adhesion signaling pathways.

31 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAbhishek Saxena
Abhishek Saxena
JSJo Stevens
Jo Stevens
HCHakan Cetin
Hakan Cetin
IKInga Koneczny
Inga Koneczny
RWRichard Webster
Richard Webster
PMPilar Martinez
Pilar Martinez
We report here the sequence and functional characterization of a recombinantly expressed autoantibody (mAb 131) previously isolated from a myasthenia gravis patient by immortalization of thymic B cells using Epstein-Barr virus and TLR9 activation. The antibody is characterized by a high degree of somatic mutations as well as a 6 amino acid insertion within the VHCDR2. The recombinant mAb 131 is specific for the γ-subunit of the fetal AChR to which it bound with sub-nanomolar apparent affinity, and detected the presence of fetal AChR on a number of rhabdomyosarcoma cell lines. Mab 131 blocked one of the two α-bungarotoxin binding sites on the fetal AChR, and partially blocked the binding of an antibody (mAb 637) to the α-subunit of the AChR, suggesting that both antibodies bind at or near one ACh binding site at the α/γ subunit interface. However, mAb 131 did not reduce fetal AChR ion channel currents in electrophysiological experiments. These results indicate that mAb 131, although generated from an MG patient, is unlikely to be pathogenic and may make it a potentially useful reagent for studies of myasthenia gravis, rhabdomyosarcoma and arthrogryposis multiplex congenita which can be caused by fetal-specific AChR-blocking autoantibodies.